XORTX Therapeutics (XRTX) announces receipt of notification that the patent “Xanthine Oxidase Inhibitor Formulations” will be granted by the European Patent Office. The patent covers compositions and methods of formulating using XORTX’s proprietary formulations of xanthine oxidase inhibitors, XOI, for the treatment of health consequences of chronically high uric acid, gout, renal, cardiovascular and other diseases where aberrant purine metabolism has been implicated in disease progression.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRTX:
- XORTX Receives Nasdaq Notification for Minimum Bid Price Deficiency
- Xortx Therapeutics discloses Nasdaq notification regarding minimum bid price
- XORTX Therapeutics Releases Annual Information Form for 2024
- XORTX Therapeutics Faces Financial Challenges Amidst Operational Losses
- XORTX Advances Gout Treatment Program with FDA Discussions